News | January 25, 2012

Crossboss CTO Catheter, Sapien, Watchman Among Picks for Best Cardiac Devices of 2011


January 25, 2012 — Which Medical Device announced the winner of its Device of the Year Award 2011 in the cardiology category. The expert panel of judges reviewed the nominations for the most significant, innovative and invaluable devices, and the winner and runners-up in the cardiology category are:

Winner

The winner of the cardiology category is the CrossBoss CTO Catheter manufactured by BridgePoint Medical. Which Medical Device Senior Editor for Cardiology Azfar Zaman commends this novel piece of technology with a good success rate in opening chronic occlusions, saying, “It is a quantum leap in the world of CTOs.”

Runner-up

The judges chose both the SAPIEN Transcatheter Heart Valve from Edwards Life Sciences and Medtronic’s Corevalve. The panel commented that, “Both these devices have stood the test of time and the medium term (five years) performance of both valves is sufficiently robust to hope that TAVI may well become the first preferred option in patients with aortic stenosis.”

Special commendations

Special mention is given to the Watchman device from Boston Scientific, which has the potential to improve lives by stopping the need for warfarin in patients with atrial fibrillation.

The judging panel also praised the Absorb Bioresorbable Vascular Scaffold from Abbott Vascular, saying  “We believe that this is the next generation for stents; it promises much but needs to deliver.”

For more information: www.whichmedicaldevice.com, www.sagepublications.com

 


Additional Content

News | Heart Valve Technology

Oct. 21, 2026 — Edwards Lifesciences Corp. recently announced that the U.S. Food and Drug Administration (FDA) has ...

Home October 23, 2026
Home
News | Heart Valve Technology

Sept. 22, 2026 — Following transcatheter aortic valve implantation (TAVI), disturbances in the heart’s electrical ...

Home September 25, 2026
Home
News | Heart Valve Technology

Sept. 22, 2026 — Researchers at the Icahn School of Medicine at Mount Sinai have received a $3.6 million, four-year ...

Home September 24, 2026
Home
News | Heart Valve Technology

June 29, 2026 — Laplace Interventional recently announced that the U.S. Food and Drug Administration (FDA) has approved ...

Home July 02, 2026
Home
Feature | Heart Valve Technology | Kyle Hardner

Primary care providers (PCPs) stand on the front lines of diagnosing clinically significant valvular heart disease (VHD) ...

Home July 01, 2026
Home
Subscribe Now